Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 microg Versus Placebo. The REACT Trial.

Trial Profile

Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 microg Versus Placebo. The REACT Trial.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Roflumilast (Primary) ; Beta 2 adrenergic receptor agonists; Corticosteroids; Muscarinic receptor antagonists
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACT
  • Sponsors Takeda; Takeda Pharma
  • Most Recent Events

    • 24 May 2017 Results of pooled analysis from REACT and RE2SPOND studies evaluating the efficacy of roflumilast in the overall population and in patients with a history of COPD-related hospitalization presented at the 113th International Conference of the American Thoracic Society.
    • 16 Jun 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 May 2013 Planned end date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top